INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
16/01/2026
Voltar para busca
Dado oficial do USPTO
S SANTONIKA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
17/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
30/03/2017
Data de registro
30/10/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/05/2025
Última transação
17/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
LU
Examinador
GOODSAID, IRA
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a shield in blue with a snake forming a letter "S" across it in light blue, next to the term, "SANTONIKA" in stylized letters in blue with horizontal bars in letters "A" in light blue.
Titulares e representantes
Titulares
M. S. (pessoa física)
Representantes
Elena A. Vodyahina
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of brainmental and nervous system disordersvertigocardiovascular issuesstrokesneurodegenerative diseasesinfectionsatherosclerosisattention deficit disorderhyperpiesisneuroticismpsychosomatic diseasesstress disordersasthenic syndromeneurotoxicosis and obesity; veterinary preparations for the treatment of neuroticism and stress disorders; pharmaceuticals and veterinary preparations for use in the treatment of diabetes and complications from diabetesinsulin resistanceinflammation and inflammatory diseasesrespiratory and infectious diseasesnasal congestioncoughsfevercoldsfluimmunological problemsfungal infectionsviral infectionsherpeschicken poxmononucleosishemorrhagic feverencephalitisbacterial infectionspseudotuberculosiswhooping coughyersiniosis and pneumonia; antibacterial preparations; antihistamines; pharmaceutical preparations for the treatment of AIDS and HIV infection; psychotropics; pharmaceutical preparations for the treatment of erectile dysfunctionbenign prostatic hyperplasiaprostatitisdysuric disordersmenopause; pharmaceutical preparations for improving digestion and reducing flatulence; pharmaceutical preparations for the treatment of irritable bowel syndrome and gastrointestinal disorders; anticonvulsants; antianxiety preparations; cough treatment preparations; pharmaceutical preparations for the treatment of respiratory tract infection; pharmaceutical preparations for the treatment of rheumatic arthritisosteoarthrosisarthropathy and ulcerative colitis; pharmaceutical antihypoxic preparations for use in the treatment of respiratorypulmonary and circulatory diseases; antioxidants; pharmaceutical vasoprotective preparations for use in the treatment of blood disordershemorrhoidsvaricose veins and vascular diseases; pharmaceutical antihyperglycemic preparations for use in the treatment of elevated levels of glucose and glycated hemoglobin in the blood; pharmaceutical preparations for the treatment of alcohol and nicotine addiction; homeopathic supplements; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the prevention and treatment of mental and neurological disorders and conditions; psychoactive pharmaceutical preparations; anxiolyticsnootropicspsycholepticssedativesantidepressants and neuroleptics; pharmaceutical preparations which stimulate the parasympathetic nervous systemenhance memory functionprevent and alleviate stress and attention deficit disorder; lactose for pharmaceutical purposes; capsules sold empty for pharmaceuticals; vitamin preparations; medical preparations for slimming purposes; nerve calming preparations for medical purposes; appetite suppressant pills
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
C71T
CANCELLED SECTION 71
16/05/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/03/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/02/2019
FIMP
FINAL DISPOSITION PROCESSED
07/02/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/01/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
30/10/2018
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
23/09/2018
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
13/06/2018
UNDN
UNDELIVERABLE MAIL - NO ACTION TAKEN
24/05/2018
PUBO
PUBLISHED FOR OPPOSITION
15/05/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/05/2018
NPUB
NOTICE OF PUBLICATION
25/04/2018
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/04/2018
CNEA
EXAMINERS AMENDMENT MAILED
22/03/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/03/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
21/03/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/03/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2018
RFNT
REFUSAL PROCESSED BY IB
10/02/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/01/2018
RFRR
REFUSAL PROCESSED BY MPU
25/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/01/2018
CNRT
NON-FINAL ACTION WRITTEN
17/01/2018
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
17/01/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/01/2018
CNRT
NON-FINAL ACTION WRITTEN
02/01/2018
DOCK
ASSIGNED TO EXAMINER
02/01/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/01/2018
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
29/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/12/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace S SANTONIKA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.